FDA Approves Stimufend (pegfilgrastim-fpgk), a Biosimilar to Neulasta

September 6, 2022 -- Fresenius Kabi, a global health care company that specializes in pharmaceuticals, medical technologies, and nutrition products for critical and chronic conditions, announced today that the United States (U.S.) Food and Drug...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news